Stock listing

Munich:1IJ Adicet Bio, Inc. Aktie

German listing (Munich) of Adicet Bio, Inc. · home listing NASDAQ:ACET

Follow Adicet Bio, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ACET

$2.14 USD -0.36 (-14.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACET

Past year -76.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.12 – $2.53 USDNov 20, 2026
Volume
760,371 sharesNov 20, 2026
Market cap
$20.03M USDAt the close on Nov 20, 2026 · price × 9.36M shares outstanding
52-week range
$2.12 – $11.15 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.45M USDMedian day 175,924 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Adicet Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACET · Home$2.14 USD-0.36 (-14.4%)760,371$2.43$2.53$2.12$2.50Close on Nov 20, 2026
LSE:0HX7$2.23 USD-0.325 (-12.7%)390$2.43$2.50$2.23$2.555Close on Nov 20, 2026
Frankfurt:1IJ€1.89 EUR-0.29 (-13.3%)—€1.93€1.93€1.89€2.18Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACET · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.14-0.36-14.4%$2.43$2.53$2.12760,371
$2.50-0.28-10.1%$2.75$2.78$2.40832,756
$2.78+0.03+1.1%$2.72$2.84$2.60389,560
$2.75-0.03-1.1%$2.80$2.88$2.60595,392
$2.78-0.15-5.1%$2.92$2.92$2.73286,376
$2.93-0.06-2.0%$2.96$3.079$2.84371,394
$2.99-0.01-0.3%$3.005$3.16$2.93416,462
$3.00+0.01+0.3%$3.00$3.08$2.86382,730
$2.99-0.06-2.0%$3.11$3.20$2.925174,755
$3.05+0.13+4.5%$2.89$3.144$2.89253,929
$2.92-0.18-5.8%$3.03$3.05$2.87420,208
$3.10-0.07-2.2%$3.26$3.31$2.99292,327
$3.17-0.03-0.9%$3.20$3.34$3.13175,831
$3.20-0.22-6.4%$3.42$3.465$3.18250,304
$3.42-0.16-4.5%$3.74$3.74$3.33242,464
$3.58-0.23-6.0%$3.83$3.86$3.56175,924
$3.810.000.0%$3.80$3.86$3.71178,815
$3.81-0.13-3.3%$3.94$3.95$3.77178,103
$3.94-0.05-1.3%$4.00$4.055$3.81162,460
$3.99-0.29-6.8%$4.22$4.29$3.96162,437
$4.28-0.21-4.7%$4.50$4.72$4.21156,957
$4.49-0.03-0.7%$4.52$4.736$4.44181,834
$4.52-0.01-0.2%$4.53$4.715$4.49126,511
$4.53-0.04-0.9%$4.57$4.745$4.39230,315
$4.57-0.57-11.1%$5.14$5.14$4.57188,500
$5.14+0.25+5.1%$4.90$5.17$4.88155,100
$4.89-0.22-4.3%$5.10$5.27$4.80357,800
$5.11-0.42-7.6%$5.53$5.53$5.10326,900
$5.53-0.08-1.4%$5.55$5.84$5.17145,900
$5.61-0.13-2.3%$5.72$6.05$5.605189,800
$5.74-0.44-7.1%$6.16$6.17$5.55487,600
$6.18-0.07-1.1%$6.21$6.44$6.12214,300
$6.25-0.22-3.4%$6.52$6.55$6.21135,500
$6.47-0.03-0.5%$6.53$6.69$6.28152,700
$6.50-0.14-2.1%$6.70$6.82$6.50164,700
$6.64-0.50-7.0%$7.06$7.17$6.64148,900
$7.14+0.31+4.5%$6.80$7.28$6.71210,800
$6.83+0.48+7.6%$6.41$7.06$6.37666,600
$6.35-2.67-29.6%$7.96$7.96$6.252,149,000
$9.02+0.75+9.1%$8.29$9.11$8.29638,600
$8.27-0.22-2.6%$8.49$8.49$7.89358,500
$8.49-0.655-7.2%$9.12$9.311$8.42262,500
$9.145+0.215+2.4%$9.00$9.44$8.98187,800
$8.93-0.25-2.7%$9.23$9.24$8.78249,500
$9.18+0.17+1.9%$8.96$9.405$8.76114,200
$9.01-0.04-0.4%$9.20$9.33$8.86130,700
$9.05+0.545+6.4%$8.52$9.44$8.445258,000
$8.505-1.195-12.3%$9.70$9.70$7.905479,000
$9.70+0.18+1.9%$9.51$9.84$9.42124,800
$9.52-0.01-0.1%$9.65$9.80$9.38119,300
$9.53-0.01-0.1%$9.46$9.68$9.31119,000
$9.54-0.19-2.0%$9.67$9.95$9.43592,900
$9.73+0.14+1.5%$9.61$9.97$9.3881,800
$9.59+0.16+1.7%$9.33$9.76$9.26144,500
$9.43+0.17+1.8%$9.26$9.64$9.04878,800
$9.260.000.0%$9.35$9.65$9.00161,000
$9.26+0.56+6.4%$8.87$9.45$8.77134,100
$8.70-0.36-4.0%$8.92$9.07$8.62111,900
$9.06+0.05+0.6%$9.22$9.245$8.76111,600
$9.01+0.06+0.7%$9.00$9.18$8.841259,800
$8.95-0.05-0.6%$8.98$9.04$8.63119,300
$9.00+0.10+1.1%$8.98$9.145$8.7869,875
$8.90-0.29-3.2%$9.21$9.21$8.7464,334
$9.19-0.19-2.0%$9.42$9.63$9.1080,500
$9.38-0.11-1.2%$9.616$9.647$9.0865,500

Splits

2 splits since 2020 · NASDAQ:ACET · every price before a split is adjusted for it

DayRatioWhat
1-for-16Consolidation
1-for-7Consolidation
Ticker
Munich:1IJ
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Latest news

Amendment to Annual Report (Form 10-K/A)

May 20, 2026

Closed $7.89 (+1.7%) on May 21, 2026

All Adicet Bio, Inc. news

Adicet Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 38 in all · newest Oct 30, 2026 · oldest 2020
Decks
24 decks · latest Sep 28, 2026

Where Adicet Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACET · Home listingNASDAQUnited StatesUSD
LS Exchange:A41X5VLS ExchangeGermanyEUR
BOATS:ACETBOATSUnited StatesUSD
Lang & Schwarz:A41X5VLang & SchwarzGermanyEUR
LSE:0HX7LSEUnited KingdomUSD
Dusseldorf:1IJDusseldorfGermanyEUR
Frankfurt:1IJFrankfurtGermanyEUR
gettex:1IJgettexGermanyEUR
Munich:1IJ · This pageMunichGermanyEUR
Tradegate:1IJTradegateGermanyEUR

Valuation

Price/book 0.2× against a median of 1.2×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.02M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
2.02

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
ZYUS Life Sciences Corporation · TSXV:ZYUSUS$20.92MUS$25.65Mn/a98.4×n/an/an/an/a-0.02
Xbrane Biopharma AB · OMXSTO:XBRANEUS$20.88MUS$23.48Mn/a1.9×n/a0.4×−49.0%0.1×n/a
Vivoryon Therapeutics N.V. · EURONEXT:VVYUS$20.48MUS$17.77Mn/an/an/a11.9×n/a0.1×n/a
Evaxion A/S · NASDAQ:EVAXUS$20.30MUS$13.40Mn/a1.8×n/a2.1×−115.1%0.8×0.78
Aardvark Therapeutics, Inc. · NASDAQ:AARDUS$20.20M−US$39.58Mn/an/an/a0.3×n/a0.0×3.28
GenSight Biologics SA · EURONEXT:SIGHTUS$20.19MUS$32.44Mn/a29,573×n/an/an/an/an/a
TransCode Therapeutics, Inc. · NASDAQ:RNAZUS$20.07MUS$15.44Mn/an/an/a0.6×n/a0.0×1.03
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Median of the othersUS$20.19MUS$18.35M50.1×1.2×−82.1%0.0×1.03

Forecasts

6 strong buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
29.00 USD · Analysts' mean
EPS, year to Dec 2026
-7.36 · 5 analysts

Team and board

Officers

OfficerRole
Chen SchorDirector, President and Chief Executive Officer
Lloyd KlicksteinInterim Chief Medical Officer/ Board of Directors

Board

DirectorRole
Andrew SinclairLead Director
Chen SchorDirector, President and Chief Executive Officer
Jeffrey A. ChodakewitzDirector
Lloyd KlicksteinInterim Chief Medical Officer/ Board of Directors
Michael GrissingerDirector
Steve DubinMember of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+4.5%
Q2 2026Aug 5, 2026 · After close−13.4%
Q1 2026May 13, 2026 · After close+4.2%
Q4 2025Mar 5, 2026−3.7%
Q3 2025Nov 5, 2025 · After close−1.9%
Q2 2025Aug 7, 2025 · After close−9.6%
Q1 2025May 6, 2025 · After close−18.6%
Q4 2024Mar 17, 2025 · Before open−0.7%
Q3 2024Nov 6, 2024 · After close+2.3%
Q2 2024Aug 13, 2024 · Before open+2.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+5.3%
Q4 2023Mar 19, 2024 · After close+5.4%
Q3 2023Nov 8, 2023 · After close−6.0%
Q2 2023Aug 9, 2023 · After close+11.9%
Q1 2023May 9, 2023 · After close+3.0%
Q4 2022Mar 15, 2023 · After close0.0%
Q3 2022Nov 8, 2022 · After close+1.2%
Q2 2022Aug 10, 2022 · Before open−3.8%
Q1 2022May 12, 2022 · After close+11.3%
Q4 2021Mar 15, 2022 · After close+22.9%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical30 slidesSep 28, 2026
Investor Presentation (September 2026)Investor deck34 slidesSep 8, 2026
Corporate Update (October 2025)Corporate update31 slidesOct 7, 2025
27th ASGCT Annual Meeting 2024Conference16 slidesMay 10, 2024
Investor Presentation (January 2024)Investor deck37 slidesJan 16, 2024
27th ASGCT Annual Meeting 2024Conference16 slides2024
American College of Rheumatology (ACR) Annual Meeting 2024Conference15 slides2024
Technical Presentation (November 2022)Technical53 slidesNov 10, 2022
Merger or Acquisition (September 2020)Merger or acquisition34 slidesSep 16, 2020
resTORbio — Merger or Acquisition (July 2020)Merger or acquisition39 slidesJul 28, 2020
All 24 decks
DeckKindSlidesDate
resTORbio — Merger or Acquisition (June 2020)Merger or acquisition39 slidesJun 23, 2020
resTORbio — Merger or Acquisition (June 2020)Merger or acquisition35 slidesJun 2, 2020
resTORbio — Merger or Acquisition (April 2020)Merger or acquisition32 slidesApr 29, 2020
resTORbio — Investor Presentation (February 2020)Investor deck27 slidesFeb 19, 2020
resTORbio — Investor Presentation (December 2019)Investor deck23 slidesDec 3, 2019
resTORbio — Guggenheim Healthcare Talks Neuro/Immunology Day 2019Conference22 slidesNov 18, 2019
resTORbio — Technical Presentation (October 2019)Technical24 slidesOct 3, 2019
resTORbio — Investor Presentation (March 2019)Investor deck42 slidesMar 18, 2019
resTORbio — Investor Presentation (February 2019)Investor deck40 slidesFeb 7, 2019
resTORbio — Investor Presentation (February 2019)Investor deck48 slidesFeb 7, 2019
resTORbio — Investor Presentation (January 2019)Investor deck44 slidesJan 7, 2019
resTORbio — Investor Presentation (October 2018)Investor deck36 slidesOct 16, 2018
resTORbio — Investor Presentation (July 2018)Investor deck33 slidesJul 30, 2018
resTORbio — Technical Presentation (July 2018)Technical19 slidesJul 25, 2018

Open Decks

Financings

RaiseDate
Registered direct offering of common stock and pre-funded warrants
Announced: about US$80M · US$1 a share · Jefferies +4
Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead), Wedbush PacGrow, H.C. Wainwright & Co.
Oct 7, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as resTORbio, Inc. Priced at US$15.00 a share on Jan 25, 2018.

Price
US$15.00 a share
Shares offered
5,666,667 shares of common stock
Offering size
US$85 million
Underwriters' option
Up to 850,000 more shares
Underwriters
BofA Merrill Lynch, Leerink Partners, Evercore ISI, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Jan 30, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceOct 27, 2017
Filed publiclyDec 29, 2017
Amended onceJan 16, 2018
Shares registered with an exchangeJan 22, 2018
Declared effective by the SECJan 25, 2018
Final prospectus, with the priceJan 29, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Jan 29, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00025.0M9.73M17.9M995.0K8.18M558.5M547.0M
Cost of revenue6.38M6.47M6.10M5.01M125.0K80.0K5.00K411.5M
Gross profit-6.38M-6.47M-6.10M25.0M9.73M17.9M995.0K8.10M558.5M135.4M
Research and development99.1M99.3M106.0M71.2M48.9M34.3M23.7M14.7M16.8M5.94M
Selling, general and administrative23.0M28.3M26.5M26.3M22.2M22.8M8.69M8.43M76.8M73.2M
Operating income-122.1M-127.6M-152.0M-72.6M-61.4M-39.2M-31.4M-15.0M-18.9M-1.00K
Depreciation and amortization6.38M6.47M6.10M2.58M1.54M1.23M1.24M1.22M5.00K11.8M
EBITDA-115.7M-121.1M-145.9M-70.0M-59.9M-38.0M-30.1M-13.7M-18.9M11.8M
Interest expense36.0K4.00K25.0K80.0K176.0K134.0K7.00M3.95M
Income before tax-116.8M-117.1M-142.7M-69.8M-62.1M-39.5M-28.1M-9.89M-33.8M-1.00K
Income tax0000-125.0K-2.81M19.0K-589.0K020.4M
Net income-116.8M-117.1M-142.7M-69.8M-62.0M-36.7M-28.1M-9.30M-33.8M-1.00K
Earnings per share, basic-16.95-21.33-3.31-1.70-2.00-5.01-13.15-4.78-8.42-0.00
Earnings per share, diluted-16.95-21.33-3.31-1.70-2.00-5.01-13.15-4.78-8.42

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents38.9M56.5M159.7M257.7M277.5M84.3M10.6M9.47M53.3M66.8M
Short-term investments119.6M119.8M0010.3M51.8M101.0M0881.0K
Receivables342.0K435.0K214.0K2.73M935.0K260.9M167.6M
Inventory2.57M4.68M-3.09M672.0K136.4M98.1M
Current assets160.9M180.1M162.3M261.0M282.4M100.3M64.2M109.5M55.2M352.7M
Property, plant and equipment16.5M22.5M26.8M28.7M14.6M2.79M2.12M321.0K39.0K
Goodwill019.5M19.5M20.1M237.0M67.9M
Total assets192.4M220.2M207.3M330.7M338.9M153.8M81.6M109.9M55.2M540.8M
Accounts payable4.74M4.83M2.63M4.40M3.26M1.55M1.05M2.99M1.51M46.0M
Current liabilities21.5M19.4M19.3M19.7M16.3M22.5M14.9M5.72M5.50M98.9M
Total debt14.7M17.2M20.9M21.0M20.9M21.6M114.1M3.11M353.7M118.8M
Total liabilities33.1M33.6M37.1M38.4M35.8M44.0M27.9M5.74M5.50M236.3M
Shareholders' equity159.2M186.6M170.2M292.3M303.1M109.8M-60.4M-33.5M-26.9M304.4M
Shares outstanding9.59M5.16M43.3M43.0M39.7M39.7M2.16M28.1M5.66M1.75M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-95.2M-92.4M-93.7M-44.8M-51.1M-41.6M-27.9M-18.2M-11.0M8.34M
Capital spending-1.74M-1.12M-4.46M-16.8M-13.0M-990.0K-1.07M-876.0K-44.0K-617.0K
Free cash flow-97.0M-93.5M-98.2M-61.5M-64.1M-42.5M-29.0M-19.1M-11.0M7.73M
Cash from investing2.39M-119.2M-4.46M-16.8M-2.80M115.2M-47.9M-16.1M-44.0K-8.97M
Cash from financing75.2M111.3M236.0K41.5M242.7M303.0K76.9M11.0M64.4M-8.24M
Dividends paid-7.08M-6.96M
Share buybacks-150.0K-3.23M-55.7M-66.8M
Change in cash-17.6M-100.3M-97.9M-20.0M188.8M74.0M1.13M-23.2M53.3M-8.88M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 13, 2026Management or board changeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 23, 2026Big-stake noticeSEC
8-K · Current reportSep 28, 2026Current reportSEC
8-K · Current reportSep 8, 2026Current reportSEC
8-K · Current reportSep 1, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
10-K/A · Annual report, amendedMay 20, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
S-8 POSMay 13, 2026Offer documentSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
8-K · Current reportApr 28, 2026FinancingSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 13, 2026Big-stake noticeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 10, 2026Big-stake noticeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
144 · Notice of proposed saleApr 9, 2026Other filingsSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
144 · Notice of proposed saleApr 7, 2026Other filingsSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 24, 2026Other filingsSEC
CORRESP · Letter to the SECMar 19, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 18, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
S-3 · Registration statementMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2026Big-stake noticeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
8-K · Current reportJan 7, 2026Current reportSEC
8-K · Current reportDec 29, 2025Current reportSEC
8-K · Current reportDec 19, 2025Meeting outcomeSEC
DEF 14A · Proxy statementNov 17, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementNov 5, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 10, 2025Big-stake noticeSEC
8-K · Current reportOct 7, 2025Current reportSEC
8-K · Current reportOct 7, 2025Material contractSEC
424B5 · ProspectusOct 7, 2025Offer documentSEC
8-K · Current reportOct 7, 2025Current reportSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
S-8 · Registration statement for employee plansJul 25, 2025Offer documentSEC
8-K · Current reportJul 23, 2025Current reportSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 21, 2025Insider tradeSEC
8-K · Current reportApr 17, 2025Management or board changeSEC
8-K · Current reportApr 11, 2025Current reportSEC
S-8 POSMar 26, 2025Offer documentSEC
424B5 · ProspectusMar 18, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 17, 2025Other filingsSEC
CORRESP · Letter to the SECMar 12, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 11, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
S-3 · Registration statementMar 6, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
8-K · Current reportFeb 5, 2025Current reportSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 23, 2025Insider tradeSEC
8-K · Current reportDec 19, 2024Current reportSEC
8-K · Current reportNov 27, 2024Current reportSEC
8-K · Current reportNov 18, 2024Current reportSEC
8-K · Current reportNov 15, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
8-K · Current reportOct 16, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 8, 2024Big-stake noticeSEC
8-K · Current reportSep 30, 2024Current reportSEC
8-K · Current reportSep 19, 2024Current reportSEC
8-K · Current reportSep 10, 2024Current reportSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2024Insider tradeSEC
8-K · Current reportAug 19, 2024Management or board changeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
8-K · Current reportJul 8, 2024Current reportSEC
8-K · Current reportJun 24, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Management or board changeSEC
144 · Notice of proposed saleJun 5, 2024Other filingsSEC
8-K · Current reportJun 5, 2024Current reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
8-K · Current reportMay 10, 2024Current reportSEC
DEFR14AApr 26, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
8-K · Current reportApr 22, 2024Current reportSEC
PRE 14A · Preliminary proxy statementApr 12, 2024Meeting noticeSEC
8-K · Current reportMar 22, 2024Material contractSEC
424B5 · ProspectusMar 22, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedMar 21, 2024Big-stake noticeSEC
S-8 POSMar 19, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 19, 2024Offer documentSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
8-K · Current reportMar 19, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 27, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 2, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 31, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJan 29, 2024Big-stake noticeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
8-K · Current reportJan 24, 2024ResultsSEC
424B5 · ProspectusJan 24, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedJan 23, 2024Big-stake noticeSEC
424B5 · ProspectusJan 22, 2024Offer documentSEC
SC 13G · Big-stake noticeJan 19, 2024Big-stake noticeSEC
8-K · Current reportJan 16, 2024Current reportSEC
8-K · Current reportJan 4, 2024Current reportSEC
8-K · Current reportNov 13, 2023Management or board changeSEC

This page holds 200 of 683 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Adicet Bio, Inc.’s releases · as of Nov 3, 2026

Common shares
9,361,596
Fully diluted
9,361,596

Fully diluted

LineSharesAs of
Common shares9,361,596Nov 3, 2026

Share count over time

CountShares
Nov 3, 20269,361,596

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.933K10.0%US$6.66MSep 30, 2026
Orbimed Advisors LLC845K9.0%US$6.03MSep 30, 2026
Franklin Templeton724K7.7%US$2.24MSep 30, 2026
Vanguard419K4.5%US$2.99MSep 30, 2026
Citadel280K3.0%US$2MSep 30, 2026
Renaissance Technologies215K2.3%US$1.53MSep 30, 2026
Alyeska Investment Group, L.P.204K2.2%US$1.46MSep 30, 2026
Adage Capital Partners Gp, L.L.C.193K2.1%US$1.38MSep 30, 2026
Schonfeld Strategic Advisors LLC189K2.0%US$1.35MSep 30, 2026
Stonepine Capital Management, LLC188K2.0%US$1.34MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Carlyle Group Inc.184K2.0%US$1.32MSep 30, 2026
Acadian Asset Management LLC171K1.8%US$1.22MSep 30, 2026
UBS118K1.3%US$844KSep 30, 2026
DAFNA Capital Management LLC93,8121.0%US$670KSep 30, 2026
Trexquant Investment LP89,8130.96%US$641KSep 30, 2026
Bridgeway Capital Management, LLC85,9590.92%US$614KSep 30, 2026
Geode Capital84,8470.91%US$606KSep 30, 2026
Two Sigma72,9150.78%US$521KSep 30, 2026
Marshall Wace, LLP69,2350.74%US$494KSep 30, 2026
Rangeley Capital, LLC64,0000.68%US$457KSep 30, 2026
Burkehill Global Management, LP62,5000.67%US$446KSep 30, 2026
BlackRock61,0240.65%US$436KSep 30, 2026
Regeneron Pharmaceuticals, Inc.60,5110.65%US$432KSep 30, 2026
Verdad Advisers, LP47,5460.51%US$339KSep 30, 2026
Dimensional38,1380.41%US$272KSep 30, 2026
State Street36,2220.39%US$259KSep 30, 2026
RBF Capital, LLC36,0820.39%US$258KSep 30, 2026
Jane Street25,9800.28%US$185KSep 30, 2026
Prelude Capital Management, LLC24,8620.27%US$178KSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.23,3080.25%US$166KSep 30, 2026
Johnson & Johnson22,7790.24%US$163KSep 30, 2026
Northern Trust18,4360.20%US$132KSep 30, 2026
Engineers Gate Manager LP12,9500.14%US$92,463Sep 30, 2026
Susquehanna12,9420.14%US$92,406Sep 30, 2026
Vontobel Holding Ltd.12,7750.14%US$91,214Sep 30, 2026
Occudo Quantitative Strategies LP12,3100.13%US$87,893Sep 30, 2026
Morgan Stanley10,8360.12%US$77,370Sep 30, 2026
Arax Advisory Partners6,0010.06%US$42,845Sep 30, 2026
Citigroup Inc4,7210.05%US$33,708Sep 30, 2026
BNP Paribas3,5730.04%US$25,511Sep 30, 2026
RBC1,9880.02%US$14,000Sep 30, 2026
Tower Research Capital LLC (TRC)1,0380.01%US$7,412Sep 30, 2026
Simplex Trading, LLC934<0.01%US$6,668Sep 30, 2026
Avion Wealth246<0.01%US$1,000Sep 30, 2026
JPMorgan201<0.01%US$1,373Sep 30, 2026
Rialto Wealth Management, LLC61<0.01%US$436Sep 30, 2026
SBI Securities Co., Ltd.35<0.01%US$250Sep 30, 2026
Caitong International Asset Management Co., Ltd28<0.01%US$200Sep 30, 2026
National Bank Of Canada17<0.01%US$121Sep 30, 2026
Barclays3<0.01%US$21Sep 30, 2026

This page holds 50 of 52 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund241K2.6%US$2.08MJun 30, 2026
Franklin Biotechnology Discovery Fund225K2.4%US$2.05MJul 31, 2026
Vanguard Extended Market Index Fund98,9121.1%US$855KJun 30, 2026
Ultra-Small Company Fund85,9590.92%US$743KJun 30, 2026
Fidelity Extended Market Index Fund47,7600.51%US$445KMay 31, 2026
iShares Micro-Cap ETF23,9400.26%US$207KJun 30, 2026
Fidelity Total Market Index Fund17,3630.19%US$162KMay 31, 2026
Dimensional U.S. Small Cap ETF14,5200.16%US$132KJul 31, 2026
U.S. Micro Cap Portfolio14,2640.15%US$130KJul 31, 2026
Fidelity Series Total Market Index Fund12,3610.13%US$115KMay 31, 2026
All 15 holders
HolderSharesOf the companyValueAs of
Fidelity Nasdaq Composite Index Fund4,8390.05%US$45,051May 31, 2026
Vanguard Institutional Total Stock Market Index Fund2,5840.03%US$22,326Jun 30, 2026
1290 VT Micro Cap Portfolio1,6010.02%US$13,833Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund1,4890.02%US$12,865Jun 30, 2026
Vanguard Balanced Index Fund786<0.01%US$6,791Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Orbimed Advisors Israel II LTD
10% owner
Sale32,523USD 6.29US$205KApr 8, 2026
Orbimed Advisors Israel II LTD
10% owner
Sale40,416USD 6.52US$264KApr 8, 2026
Orbimed Advisors Israel II LTD
10% owner
Sale29,319USD 6.53US$191KApr 7, 2026
Orbimed Advisors Israel II LTD
10% owner
Sale2,400USD 6.38US$15,312Apr 7, 2026
RA Capital Healthcare Fund LP
10% owner
Buy74,751USD 7.27US$543KFeb 20, 2026
RA Capital Healthcare Fund LP
10% owner
Buy74,268USD 7.21US$535KFeb 19, 2026
RA Capital Healthcare Fund LP
10% owner
Buy74,577USD 7.04US$525KFeb 18, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.9.90%935KJun 30, 2026Schedule 13G
Franklin Resources Inc7.70%724KSep 30, 2026Schedule 13G
Zedek Daniel Clayton5.40%502KOct 19, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Sep 15, 2020 – Aug 21, 2024 · Past
Erez Chimovits
Other companies: ADARx Pharmaceuticals, Inc. (Partner at OrbiMed Advisors · Since at least Sep 24, 2026); Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); BiomX Inc. (Director · Oct 28, 2019 – Mar 25, 2020 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Oct 1, 2020 · Past); Eledon Pharmaceuticals, Inc. (Director · May 10, 2017 – Jan 14, 2020 · Past)
Director · Sep 15, 2020 – Jun 27, 2023 · Past
Michael Kauffman
Other companies: Kyntra Bio, Inc. (Director · Since at least Jun 4, 2025); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Verastem, Inc. (President, Development · Since at least Nov 26, 2012); Karyopharm Therapeutics Inc. (Director · Nov 5, 2013 – Feb 28, 2022 · Past); EPIRUS Biopharmaceuticals Inc (Director · Jan 15, 2010 – Jun 6, 2013 · Past); Onyx Pharmaceuticals Inc (Chief Medical Officer · Nov 16, 2009 – Feb 9, 2010 · Past)
Director · Nov 17, 2021 – Aug 21, 2024 · Past
Paul Fonteyne
Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Amylyx Pharmaceuticals, Inc. (Director · Since at least Jan 6, 2022); Apellis Pharmaceuticals, Inc. (Director · Since at least Apr 2, 2020); Covetrus Inc (Director · Jul 1, 2021 – Oct 13, 2022 · Past); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past)
Director · Jan 25, 2018 – Jun 3, 2020 · Past
Jeffrey A Chodakewitz
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Apr 13, 2021); Schrodinger, Inc. (Board Member · Since at least Apr 30, 2020); Vertex Pharmaceuticals Incorporated (EVP · Jul 15, 2014 – Apr 1, 2018 · Past); Tetraphase Pharmaceuticals Inc (Director · Jun 12, 2014 – Jun 10, 2019 · Past)
Director · Since at least Aug 14, 2018
Jonathan Silverstein
Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Oct 2, 2020 · Past); Glaukos Corporation (Director · Dec 13, 2017 – Mar 2, 2018 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Nov 21, 2017 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Oct 4, 2017 · Past)
Director · Jan 25, 2018 – Jun 3, 2020 · Past
Lynne Sullivan
Other companies: Inozyme Pharma Inc (Director · Since at least Jul 23, 2020); Solid Biosciences Inc. (Chief Financial Officer at Unity Biotechnology · Since at least Jan 25, 2018); Unity Biotechnology Inc (CFO & Head of Corp. Dev. · Aug 1, 2020 – Apr 2, 2025 · Past); BiomX Inc. (Director · Nov 4, 2019 – Mar 1, 2023 · Past)
Director · Jan 25, 2018 – Jun 3, 2020 · Past
Andrew Sinclair
Other companies: Soleno Therapeutics, Inc. (Director · Since at least Dec 21, 2018); Verona Pharma plc (Director · Jan 1, 2021 – Aug 9, 2021 · Past); Sierra Oncology Inc (Director · Nov 22, 2019 – Jul 1, 2022 · Past)
Lead Director · Since at least Mar 2, 2021
Chen Schor
Other companies: Karyopharm Therapeutics Inc. (Director · Since at least Nov 25, 2020); Madrigal Pharmaceuticals, Inc. (Former President and CEO, Director · Dec 8, 2014 – Jul 22, 2016 · Past); Brainstorm Cell Therapeutics Inc. (Director · Aug 22, 2011 – Nov 30, 2018 · Past)
Director, President and Chief Executive Officer · Since at least Jan 25, 2018
Michael Grissinger
Other companies: Lipocine Inc. (Director · Since at least Aug 3, 2026); Aprea Therapeutics, Inc. (Director · Since at least May 16, 2022); Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past)
Director · Since at least Nov 5, 2018
All 27 people
PersonSeat
Stewart Abbot
Other companies: Turnstone Biologics Corp. (Chief Scientific Officer · Jul 20, 2023 – Oct 16, 2023 · Past); Fate Therapeutics, Inc. (Chief Development Officer · Oct 6, 2015 – May 15, 2018 · Past)
See Remarks · Sep 15, 2020 – Jun 11, 2021 · Past
Brian Nicholas Harvey
Other companies: Radius Health, Inc. (Sr. VP and CFO · Feb 10, 2016 – Apr 25, 2017 · Past)
Chief Financial Officer · Since at least Sep 15, 2020
Carrie Krehlik
Other companies: Global Blood Therapeutics Inc (Chief Human Resources Officer · Aug 2, 2021 – Oct 5, 2022 · Past)
Chief Human Resources Officer · Sep 15, 2020 – Feb 12, 2021 · Past
Daphne Zohar
Other companies: Seaport Therapeutics, Inc. (Founder, CEO & Board Member · Since at least Apr 30, 2026)
Director · Jan 25, 2018 – Jan 25, 2018 · Past
Don Healey
Other companies: Acer Therapeutics Inc (Chief Scientific Officer · Oct 26, 2015 – May 16, 2016 · Past)
Chief Technology Officer · Since at least Oct 26, 2020
John J McCabe
Other companies: Eleven Biotherapeutics Inc (Chief Financial Officer · Jul 3, 2015 – Apr 3, 2017 · Past)
Vice President, Finance · Jan 25, 2018 – Dec 6, 2019 · Past
Meredith Manning
Other companies: Soleno Therapeutics, Inc. (Chief Commercial Officer · Since at least Apr 22, 2024)
Chief Commercial Officer · Sep 17, 2018 – Feb 27, 2019 · Past
Steve Dubin
Other companies: Martek Biosciences Corp (Chief Executive Officer, Director · Jul 7, 2010 – Feb 25, 2011 · Past)
Director · Since at least Sep 15, 2020
Aya JakobovitsDirector · Sep 15, 2020 – Aug 21, 2024 · Past
Blake AftabChief Scientific Officer · Since at least Oct 12, 2021
David Adam SteinbergDirector · Jan 25, 2018 – Jun 3, 2020 · Past
Francesco GalimiSVP & Chief Medical Officer · Sep 15, 2020 – Jun 5, 2024 · Past
Joan MannickChief Medical Officer · Jan 25, 2018 – Dec 6, 2019 · Past
Julia D MaltzmanChief Medical Officer · Since at least Jan 13, 2025
Lloyd KlicksteinInterim Chief Medical Officer/ Board of Directors · Since at least May 13, 2019
Steve DubinMember of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee · Since at least Nov 4, 2026
Yair Chaim SchindelDirector · Sep 15, 2020 – Sep 15, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about Adicet Bio, Inc.